US FDA approves osilodrostat for treatment of Cushing's Disease

The FDA has approved osilodrostat oral tablets for adults with Cushing's disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease. The drug acts by blocking the enzyme 11-beta-hydroxylase and preventing cortisol synthesis.

SPS commentary:

The Committee for Medicinal Products for Human Use (CHMP) has already issued a positive opinion recommending approval of the drug in the EU.


US Food and Drug Administration